Literature DB >> 29907801

Comparative assessment of gene-specific variant distribution in prenatal and postnatal cohorts tested for Noonan syndrome and related conditions.

N T Leach1, D R Wilson Mathews2, L S Rosenblum2, Z Zhou2, H Zhu2, R A Heim2.   

Abstract

PURPOSE: To compare the pattern of gene-specific involvement and the spectrum of variants observed in prenatal and postnatal (mean ± SD, 8.9 ± 9.4 years) cohorts tested for Noonan syndrome and related conditions.
METHODS: Outcomes of sequencing panel testing were compared between prenatal (n = 845) and postnatal (n = 409) cohorts.
RESULTS: PTPN11 and SOS1 harbored the majority of observed variants in both prenatal and postnatal cohorts, and BRAF, HRAS, KRAS, MAP2K1, MAP2K2, RAF1, and SHOC2 had similarities in their pattern of involvement in both cohorts. PTPN11 was the largest contributor of pathogenic variants and had the lowest frequency of variants of uncertain significance (VUS). SOS1 had the highest VUS frequency in both cohorts. The overall VUS frequency was twice as high in prenatal specimens (58.1 vs. 29.3%). PTPN11 and SOS1 had a 1.5-fold higher VUS frequency in the prenatal cohort (10.7 vs. 7.4% and 95 vs. 61.1%, respectively). The diagnostic yield was 3.7% for prenatal samples, with a higher yield of 12.3% in fetuses with cystic hygroma as a sole finding, and 21.3% for postnatal.
CONCLUSION: Comparison of prenatal versus postnatal specimens demonstrates that the pattern of specific gene involvement is similar, whereas the classification spectrum of observed variants differs considerably.

Entities:  

Keywords:  Clinical indication; Detection rate; Genetic testing; Noonan syndrome; Prenatal testing

Mesh:

Substances:

Year:  2018        PMID: 29907801     DOI: 10.1038/s41436-018-0062-0

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  3 in total

Review 1.  PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.

Authors:  Tsutomu Ogata; Rie Yoshida
Journal:  Pediatr Endocrinol Rev       Date:  2005-06

Review 2.  Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.

Authors:  Alexander A L Jorge; Alexsandra C Malaquias; Ivo J P Arnhold; Berenice B Mendonca
Journal:  Horm Res       Date:  2009-03-04

3.  Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.

Authors:  Ellen Denayer; Koen Devriendt; Thomy de Ravel; Griet Van Buggenhout; Eric Smeets; Inge Francois; Yves Sznajer; Margarita Craen; George Leventopoulos; Léon Mutesa; Willy Vandecasseye; Guy Massa; Hulya Kayserili; Raf Sciot; Jean-Pierre Fryns; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2010-03       Impact factor: 5.006

  3 in total
  4 in total

1.  The sixth international RASopathies symposium: Precision medicine-From promise to practice.

Authors:  Karen W Gripp; Lisa Schill; Lisa Schoyer; Beth Stronach; Anton M Bennett; Susan Blaser; Amanda Brown; Rebecca Burdine; Emma Burkitt-Wright; Pau Castel; Sandra Darilek; Alwyn Dias; Tuesdi Dyer; Michelle Ellis; Gregg Erickson; Bruce D Gelb; Tamar Green; Andrea Gross; Alan Ho; James Lloyd Holder; Shin-Ichi Inoue; Angie C Jelin; Annie Kennedy; Richard Klein; Maria I Kontaridis; Pilar Magoulas; Darryl B McConnell; Frank McCormick; Benjamin G Neel; Carlos E Prada; Katherine A Rauen; Amy Roberts; Pablo Rodriguez-Viciana; Neal Rosen; Gavin Rumbaugh; Anna Sablina; Maja Solman; Marco Tartaglia; Angelica Thomas; William C Timmer; Kartik Venkatachalam; Karin S Walsh; Pamela L Wolters; Jae-Sung Yi; Martin Zenker; Nancy Ratner
Journal:  Am J Med Genet A       Date:  2019-12-11       Impact factor: 2.802

2.  Exome sequencing vs targeted gene panels for the evaluation of nonimmune hydrops fetalis.

Authors:  Mary E Norton; Jessica Van Ziffle; Billie R Lianoglou; Ugur Hodoglugil; W Patrick Devine; Teresa N Sparks
Journal:  Am J Obstet Gynecol       Date:  2021-07-28       Impact factor: 8.661

3.  Response to "Further genetic testing in prenatal cases of nonimmune hydrops fetalis with a normal array: a targeted panel or exome?"

Authors:  Mary E Norton; Teresa N Sparks
Journal:  Am J Obstet Gynecol       Date:  2021-10-02       Impact factor: 10.693

4.  Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.

Authors:  Leora Witkowski; Mitchell W Dillon; Elissa Murphy; Matthew S Lebo; Heather Mason-Suares
Journal:  Mol Genet Genomic Med       Date:  2020-02-27       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.